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ABSTRACT

CURCUMIN REACTIVATES EPIGENETICALLY SILENCED TUMOR
SUPPRESSOR GENE TISSUE FACTOR PATHWAY INHIBITOR-2 IN
HEPATOCELLULAR CARCINOMA CELLS
Akshata Moghe
July 1,2010

Hepatocellular carcinoma (HCC) is the fifth most common cancer
worldwide and the third most fatal, with a rising incidence in the US as a result of
the increase in alcoholic liver disease and obesity. Current therapeutic strategies
are unsatisfactory with poor treatment outcomes and efficacious therapies are
acutely needed for better management of this deadly disease. Curcumin, a
phenolic compound from the rhizome of the plant Curcuma longa has been
shown to inhibit growth and induce cell death in various types of cancer cells
including HCC. However, the anti-HCC mode of action of curcumin has not yet
been elucidated.
In HCC, aberrant promoter methylation and histone deacetylation are
implicated in the inactivation of tumor suppressor genes which has a significant
impact on carcinogenesis. Tissue factor pathway inhibitor-2 (TFPI-2), a Kunitztype serine protease inhibitor, is a tumor suppressor gene that is frequently
epigenetically silenced in human HCC and HCC cell lines. Restoration of TFPI-2
expression in tumor tissue has been shown to not only inhibit invasion, tumor

IV

growth, metastasis and angiogenesis but also induce apoptosis. We examined
the effects of curcumin on tumor suppressor genes in HCC and observed robust
reactivation of TFPI-2 in HepG2 cells upon curcumin treatment. We confirmed
that TFPI-2 was under epigenetic control in HepG2 cells by using demethylating
agent

5-Aza-2'deoxycytidine

(5-AZA)

and

histone

deacetylase

inhibitor

trichostatin A (TSA), both of which induced gene expression. Further, we
investigated the epigenetic modifications at the TFPI-2 promoter and the
alterations induced by curcumin in these epigenetic states. Histone H3
acetylation at the transcription factor binding sites of the TFPI-2 promoter region
was increased by curcumin and correlated with the induction of gene expression.
The reactivation of TFPI-2 also corresponded with a decrease in cell
invasiveness and increase in cell death in HepG2 cells. Overall, our data strongly
suggest that curcumin can reverse the epigenetic alterations at the TFPI-2
promoter and thus, reactivate this silenced tumor suppressor gene. These results
support a potential therapeutic role for curcumin in the management of HCC.
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CHAPTER I
INTRODUCTION

Hepatocellular Carcinoma (HCCl

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the
world 1-2 and the third most common cause of cancer-related mortality 1,

3.

Every

year, between 500,000 and 1000,000 new cases of HCC are detected, and
almost all of the victims die of the disease. HCC has a higher incidence in
developing countries, especially in Sub-Saharan Africa and South Asia, due to
the increased prevalence of viral hepatitis in these regions. However, this trend is
now changing and there has been an alarming rise in the incidence of HCC in
economically developed nations like Japan, Western Europe and the United
States in the past few years2. In the United States, in addition to Hepatitis C viral
(HCV) infection, the growing epidemics of alcoholic liver disease (ALD), obesity
and non-alcoholic steatohepatitis (NASH) have contributed to the rapid rise in
HCC incidence. Liver cirrhosis is a premalignant condition that greatly increases
the risk of HCC, and is common in the USA2. It is expected that the incidence of
HCC will only continue to rise in the coming years as latent HCV infections come
to

the

fore

and

as

more

and

1

more

cases

of

ALD

and

NASH

emerge and progress to cirrhosis 2-3 . The reason for the high mortality associated
with HCC is that the treatment modalities available today are minimally effective
at best. The best treatment option is liver transplantation, which is not only
expensive but also complicated in the setting of liver cirrhosis, a condition
invariably present in these patients. Moreover, most patients are diagnosed at a
late stage in the disease, and their cancers are not amenable to transplantation.
Other surgical interventions such as liver resection, percutaneous ethanol
injection,

radiofrequency

ablation,

transarterial

embolization

and

chemoembolization have been tried with unsatisfactory outcomes. Adjuvant
chemotherapy with various chemotherapeutic agents such as doxorubicin,
cisplatin, fluorouracil and interferon also yields little survival benefit. Recently,
Sorafenib, a tyrosine protein kinase inhibitor, was approved for use in HCC but
its efficacy and toxicity is still being investigated in clinical trials. If left untreated,
HCC progresses rapidly to death within 6-8 months even when diagnosed early.
Patient prognosis is poor and the 5-year survival rate utterly dismal at less than 5
percent4. As a result, there is an urgent need for the development or discovery of
a novel, effective therapy for the management of HCC.

2

Pathogenesis of HCC : relevance to tumor suppressor genes

An understanding of the process of hepatocellular carcinogenesis is critical in
order to define pertinent molecular targets for therapy. Until now, HCC had been
linked to increases in allelic losses, chromosomal changes, gene mutations and
alterations in molecular cellular pathways 5. It is now recognized that in addition to
the known genetic alterations of mutations and deletions, epigenetic alterations
can also playa major role in tumorogenesis 5 . In HCC, as in other cancers,
aberrant DNA methylation and specific histone modifications are implicated in the
development and progression of the disease 5 -7 . Aberrant DNA methylation
occurs in the form of global hypomethylation and regional hypermethylation of
CpG

islands.

The

global

hypomethylation

results

in

the

activation

of

protooncogenes. Regional hypermethylation in the promoter regions of tumor
suppressor (TS) genes leads to their transcriptional silencing and inactivation 6 ,8.
Several TS genes such as TFPI-2, RASSF1A, P16, P15 and GADD45 have been
found to be frequently epigenetically silenced through promoter hypermethylation
in HCC 8 -13 .
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Hepatocellular carcinogenesis
Normal hepatocytes

Alterations in cellular epigenome:
• Global DNA hypomethylation
• Regional hypermethylation at the
promoters of tumor suppressor genes
Epigenetically
reprogrammed hepatocytes

• Aberrant histone modifications

Compromised genomic stability
Hepatocellular
Carcinoma

Fig. 1 Epigenetic mechanisms of carcinogenesis in HCC
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Tissue Factor Pathway Inhibitor-2 (TFPI-2)

Amongst the identified TS genes, Tissue factor pathway inhibitor-2

(TFPI-2) is significantly underexpressed 14 in approximately 90 percent of
primary HCCs when compared to their corresponding non-tumorous

Ii vers9. Wong et. al. (2007) studied the gene expression profiles of several
candidate genes in HCC by microarray analysis and detected frequent
inactivation of TFPI-2 in several human HCC cell lines and human HCC samples.
Expression of TFPI-2 in HCC cell lines could be robustly restored by treatment
with known epigenetic modulators such as 5-Aza-2-deoxycytidine (5-AzadC, a
DNA methyltransferase inhibitor) and Trichostatin A (TSA, a histone deacetylase
inhibitor) , which implied that the gene was indeed under epigenetic control 9 .
TFPI-2 is a Kunitz-type serine proteinase inhibitor. Previously designated
as placental protein 5, it inhibits a broad range of serine proteinases and plays an
important role in the regulation of extracellular matrix degradation and
remodeling 15. TFPI-2 inhibits plasmin and trypsin activity and reduces cellular
invasiveness of tumors. Reduced expression of TFPI-2 has been associated with
several patho-physiological processes such as inflammation, angiogenesis,
atherosclerosis, retinal degeneration and tumor growth and metastasis 15 .
Besides HCC, TFPI-2 is inactivated in many other tumors, including esophageal,
pancreatic, gastric, colon and breast cancers 16-20. Overexpression of TFPI-2 or
upregulation of the reduced expression of TFPI-2 has the potential to limit tumor
growth by inhibiting angiogenesis, cellular proliferation and cellular invasiveness
of tumor cells 21 -22 . Restoration of TFPI-2 has also been shown to trigger

5

apoptosis through a caspase-mediated mechanism in a human glioblastoma cell

ABERRANT CpG ISLAND METHYLATION
and/or
UNFAVORABLE HISTONE MODIFICATIONS
at the TFPI-2 promoter

1
[

TFP~2 1

Matrix~~
Degradation
U
~~

MM Ps: Matrix m etalloproteinases

-Cell migrationfcell invasiveness
-Metastasis
-Angiogenesis
'Vasculogenesis
-Inflammation
-Atherosclerosi s
-Release of growth factors
'-- and cytokines

Fig.2 Proposed epigenetic mechanisms that silence tumor suppressor
gene TFPI-2 in HCC and the implications of inactivation of the gene
Modified from Chand HS et al. 15
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Importantly, in HCC as well, ectopic overexpression of TFPI-2 has been
shown to significantly suppress proliferation and invasiveness of tumor cells9 .
Taken together, these data strongly imply that loss of TFPI-2 expression is
critical to the establishment and progression of HCC. Hence, TFPI-2 is an
important target tumor suppressor gene in the treatment and control of
HCC.

Curcumin as an epigenetic modulator
Curcumin, the phenolic compound from the rhizome of the plant Curcuma
Longa (turmeric, yellow curry powder) has been used for centuries in ancient

medicine to treat various diseases. In recent years, curcumin (diferuloylmethane)
has been extensively characterized to define the mechanisms underlying its
innumerable beneficial properties. Curcumin displays a plethora of favorable
effects, including anti-inflammatory, anti-oxidant, anti-proliferative and proapoptotic effects 24-25 . Its anti-inflammatory effects are mediated through the
inhibition of inflammatory transcription factors (such as nuclear factor K8),
enzymes (such as cyclooxygenase-2 and 5-lipoxygenase) and cytokines (such
as tumor necrosis factor, interleukin 1 and interleukin

6)25.

Since most chronic

diseases involve inflammation, curcumin has been used to treat a myriad of
cardiovascular, pulmonary, neurological and metabolic diseases. The antitumorigenic properties of curcumin are being investigated in many cancers 26 and
curcumin is also being tested in human clinical trials for the treatment of colon

7

and pancreatic cancers 27 . Importantly, curcumin has been shown to possess
anti-HCC properties in in vitro and in animal studies28 -29 .

However, its exact

mechanism of action in the control of HCC is still not well-elucidated.
In our experiments, we confirmed that curcumin kills HCC cells using
HepG2, a well characterized HCC cell line. We also examined the effect of
curcumin on TFPI-2 in HepG2 cells and our preliminary data show that curcumin
was able to significantly reactivate TFPI-2 gene expression, similar to the effects
of the epigenetic modulators 5-Aza-2-deoxycytidine and Trichostatin A. These
results support a potential role for curcumin as an epigenetic modulator in its
anti-HCC action. Curcumin has recently been shown to cause epigenetic
alterations through both, histone modifications and DNA methylation 3o . However,
these alterations induced by curcumin are only beginning to be studied.

Hypothesis

The effects of curcumin appear to be complex and context-dependent as
curcumin supports histone acetylation in some cases and histone deacetylation
in others31 -32 • Moreover, there is no systematic study as yet investigating the role
of curcumin as an epigenetic modulator in HCC cells. Based on our preliminary
data, we propose that curcumin induces epigenetic modifications in HCC cells,
particularly with respect to tumor suppressor genes. Specifically, we hypothesize
that curcumin induces de-repression of the epigenetically silenced tumor

8

suppressor gene TFPI-2 in hepatocellular carcinoma (HCC) cells and that
this effect is a significant component of its anti-HCC action.
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CHAPTER II
MATERIALS AND METHODS

Reagents

Curcumin was purchased from Biomol (Plymouth Meeting, PAl. 5-Aza -2'
deoxycytidine, Trichostatin A and dimethyl sulfoxide (DMSO) were purchased
from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum was purchased from
Atlanta Biologicals (Norcross, GA). DMEM, penicillin, streptomycin and TRlzol®
were obtained from Invitrogen (Carlsbad, CA). All RT-PCR reagents were
purchased from Applied Biosystems (Foster City, CA). MTT (Thiazolyl Blue
Tetrazolium Bromide) was obtained from Sigma-Aldrich (St. Louis, MO) and the
CeIiTiter-Glo® Luminescent Cell Viability assay was obtained from Promega
Corporation (Madison, WI). The CytoSelecFM 24-Well Cell Invasion Assay was
purchased from Cell Biolabs, Inc. (San Diego, CA).

Cell Culture

HepG2 cells (clone E6-1, ATCC, Rockville, MO) were cultured in Dulbecco's
modified eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 10 U/ml penicillin, and 10

~g/ml

streptomycin. Cells were maintained in an

incubator at 37°C with humidified 5% CO 2
overnight before treatment, in all experiments.
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.

Cells were plated and incubated

RNA Isolation and Real-Time PCR Analysis

Total RNA was isolated from cells treated with curcumin, 5-AZA or T8A using
TRlzol®, according to manufacturer's instructions. For real time PCR, the first
strand cDNA was synthesized using TaqMan Reverse transcription reagents
(Applied Biosystems). The reverse transcription was carried out using 1X
Taqman RT buffer, 5.5 mM MgCI 2 , 500

~M

of each dNTP, 2.5

~M

random

hexamer, 8 U of RNase inhibitor and 25 U of Multiscribe Reverse Transcriptase
with 200ng of total RNA. The RT conditions were 10 min at 25°C, 30 min at 48°C
and 5 min at 95°C. Reactions in which the RNA was omitted served as negative
controls. Real time PCR was performed with an ABI prism 7500 sequence
detection system and 8YBR green I dye reagents.
Reverse transcriptase polymerase chain reaction (RT-PCR) assays were used to
assess TFPI-2 mRNA levels in HepG2 cells. TFPI-2 and 188 rRNA specific
primers were purchased from 8uperArray Bioscience Corporation (Frederick,
MD).

The parameter threshold cycle (C t) was defined as the fraction cycle

number at which the fluorescence passed the threshold. The relative gene
expression was analyzed using the 2-AACt method by normalizing with 188
rRNA gene expression in all the experiments.

Cell Survival Assays

The MTT assay and the CeliTiter-Glo® Luminescent Cell Viability assay were
used to assess cell survival. For the MTT assay, cells were plated in 96 well
microplates, incubated overnight and treated with curcumin for 24 hours.
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Treatments were then removed and MTT (1 mg/ml) was added in fresh OM EM
(100 Ill/well). After incubation at 37°C with humidified 5% CO2 for 1-3 hours, MTT
lysis buffer (100 Ill/well) was added. The cells were further incubated overnight
for complete lysis. Cell viability was quantified colorimetrically by measuring 0.0.
at 570 nm. The CeliTiter-Glo® Luminescent Cell Viability assay was used to
determine the number of viable cells based on the amount of ATP present.
Briefly, 10,000 cells/1001l1 per well were plated in 96 well plates. After treatment
with different concentrations of curcumin (6.25 to 50 11M) for 24 hours, an equal
volume (100111) of CeIiTiter-Glo® reagent was added to each well. Plates were
incubated at room temperature for 10min to allow complete cell lysis and
stabilization of luminescence. The Luminescent signal (RLU) was measured by
Orion luminometer.

Cell Invasion Assay

The CytoSelect™ 24-Well Cell

Invasion Assay was performed as per

manufacturer's instructions. Briefly, a suspension of 1x 106 cells/ml was prepared
in serum free media and 300 III of this suspension was placed in the upper
chamber on the rehydrated membrane. 500 III of culture medium with 10%fetal
bovine serum (chemoattractant) was placed in the lower chamber. The chamberinsert assembly was allowed to incubate for at 37°C in 5% CO 2 atmosphere.
After 24 hours, the non-invasive cells were removed, the inserts stained, washed
and allowed to air dry. Each insert was then incubated in Extraction Solution on
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an orbital shaker at room temperature. 0.0. was measured using a colorimetric
plate reader.

Chromatin Immunoprecipitation (ChiP) and gChlP PCR analysis

The ChiP assay was conducted using the ChiP assay kit according to the
manufacturer's instructions (Millipore, Billerica, MA). Briefly, 10 X 106 cells were
crosslinked with 1% formaldehyde- 1 X-glycine and lysed in lysis buffer
containing protease inhibitor cocktail.

Enzymatic digestion of DNA was

performed as per manufacturer's protocol (EZ-Zyme Magna CHIP KIT) to
produce chromatin fragments of 100-166 bp. ChiP antibody directed against
acetyl-histone

H3

(Lys9,

14)

(Millipore,

Billerica,

MA),

was

used

for

immunoprecipitation. The Iysates were incubated overnight with antibody,
following which the antibody/protein complexes were immunoprecipated using
magnetic beads. Successive washes were performed with low salt, high salt, LiCI
and Tris EDTA (TE) wash buffers. After reverse crosslinking and purification,
pure DNA was eluted in elution buffer (1 % SDS, 0.1 M NaHC03). qChIP-PCR
was performed using the ABI Prism 7500 Sequence Detection System. ChIPPCR primers designed for two regions of the TFPI-2 promoter were used and
their sequences are as follows:
ChiP TFPI-2 (I) LP
RP
ChiP TFPI-2 (II) LP
RP

GGCTTCTTTACAGCGCAATC
ACCTGCCTCCCAAACTTTCT
ACAGTCCCCGTGCATGAAT
GCAAGGCGTCCGAGAAAG
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Data was analyzed as Differential Occupancy Fold Change. ChIP-qPCR results
were calculated

by llllCt method (since all Ct values for a binding site are

determined from the same qPCR assay) where each ChiP DNA fractions Ct
value was normalized to the Input DNA fraction Ct value using llCt [normalized
ChiP]

= (Ct

[ChiP] - (Ct [Input] - Log2 (Input Dilution Factor))). The difference

between the normalized experimental sample (S2) and the control sample (S1)
ChiP fraction Ct values (second llllCtt) was determined using llllCt [S2-S1]

=

llCt [S2: normalized ChiP] - llCt [S1: normalized ChiP].

Bisulfite treatment and methyl-specific peR

DNA was extracted from untreated and curcumin-treated cells using the DNeasy
tissue kit and DNA samples were treated with bisulfite (EZ DNA methylation Gold
Kit from Zymo) following the manufacturer's protocol. Human un methylated DNA
(Qiagen) and human methylated DNA (Active Motif) were used as controls. The
bisulfite-converted samples and controls were then amplified with primer pairs
specific for bisulfite converted methylated DNA and un methylated DNA .The PCR
reaction uses 10 ng of the bisulfite treated DNA in a 25 III reaction. Standard
PCR conditions were employed at an optimized annealing temperature. The
products were analyzed on a 1.4% agarose gel. The methylation-specific primer
sets have been derived from experiments performed by Glockner et. al. 19 and
have been tested in our laboratory. The primer set most sensitive to methylation
differences at positions -93 and -32 (with respect to the TSS) of the TFPI-2
promoter was used, and the primer sequences for this set are shown below. 'M'

14

stands for the methylated DNA-specific primer and 'U' stands fot the
un methylated DNA-specific primer:

TFPI2(Glockner)-M(1 )-L

CGGCGGGGTGATAGTTTTC

TFPI2(Glockner)-M(1 )-R

CAAACGACCCGAATACCCGCTTTATACG

TFPI2(Glockner)-U(1 )-L

GTGGTGGGGTGATAGTTTTTG

TFPI2(Glockner)-U(1 )-R

CCAAACAACCCAAATACCCACTTTATACA

Table (1) Methyl-specific Real-Time peR primers for a single
region of the TFPI-2 promoter

Statistical Analysis

Data are presented as means± SO for the indicated number of
independently performed experiments. Student's t-test and one-way ANOVA with
Tukey's multiple comparison test were used for the determination of statistical
significance. P<O.05 was considered significant.
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CHAPTER III
RESULTS

Curcumin reactivates TFPI-2 in HepG2 cells

TFPI-2 is an important tumor suppressor gene that is significantly
underexpressed in most HCC cell lines and primary HCCs.

Hence, this gene

likely plays a key role in the development and establishment of HCC. We
therefore examined whether treatment with curcumin affects the expression of
this critical tumor suppressor in HepG2 cells
HepG2 cells were plated at a density of 0.5 x 106 cells/ml and incubated
overnight under standard conditions. The cells were then treated with 25 11M
curcumin for 24 hours and RNA was obtained as described earlier, for RT-PCR
analysis.
Curcumin induced a robust expression of TFPI-2 at 24 hours (fig. 3).
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TFPI-2 mRNA expression in
HepG2 cells
*
7
6

~5

~
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CUR25j.JM

UT

Fig. 3 Curcumin-induced TFPI-2 expression in HCC cells.

HepG2 cells were left untreated (UT) or treated with curcumin (25

~M)

for 24

hours. TFPI-2 mRNA expression is normalized to 18S rRNA expression and
shown as fold over untreated. Data is presented as mean ± SO, n=3; * p<O.05
when compared to UT
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TFPI-2 is under epigenetic control in HepG2 cells

It has been shown in previous studies that TFPI-2 is frequently repressed
in HCC cells by epigenetic mechanisms such as DNA methylation and histone
deacetylation. We examined the epigenetic regulation of TFPI-2 in HepG2 cells
using two known epigenetic modulators, 5-Aza-2'deoxycytidine (5-AZA) and
Trichostatin A (TSA). 5-AZA is a DNA methyltransferase (DNMT) inhibitor and
functions as a demethylating agent. TSA is a histone deacetylase (HDAC)
inhibitor and allows acetylation of histone residues. 5-AZA and TSA thus,
promote transcriptionally permissive epigenetic states, by causing CpG island
demethylation

and

histone

acetylation,

respectively,

at

promoters

of

epigenetically regulated genes.
Both 5-AZA and TSA derepressed TFPI-2 leading to the induction of gene
expression, demonstrating that TFPI-2 is indeed controlled by histone acetylation
and DNA methylation in HepG2 cells (fig. 4). In comparison to 5-AZA, TSA
induced TFPI-2 expression to a greater extent, suggesting that histone
acetylation likely plays a predominant role in regulating the transcriptional
induction of TFPI-2 gene. Further experiments at longer time pOints are required
to completely characterize the effects of these agents.

18

TFPI-2 m RNA in epigenetic
modulator treated HepG2 cells
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Fig. 4 TFPI-2 is epigenetically regulated in HepG2 cells

HepG2 cells were left untreated (UT) or exposed to 5-Aza-2'deoxycytidine 10 11M
(5-AZA) or Trichostatin A 300 ng/ml (T8A) and TFPI-2 mRNA expression was
examined at 12 and 24 hours by RT-PCR analysis. TFPI-2 mRNA expression
was normalized to 188 expression and shown as fold over untreated.
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Curcumin increases histone H3 acetylation at the TFPI-2 promoter

Since TFPI-2 is found to be epigenetically silenced in HepG2 cells, we
hypothesized that curcumin utilizes epigenetic mechanisms to derepress the
gene. Curcumin likely modifies or reverses the transcriptionally repressive
epigenetic state of the TFPI-2 promoter.

To test this hypothesis, we first

examined the acetylation status of the histone H3 at the TFPI-2 promoter using
the Chromatin Immunoprecipitation (ChiP) assay. The ChiP technique allows for
investigation of DNA-protein interactions at the regions of interest in a gene
promoter.

We designed primers that would specifically amplify TFPI-2 gene

promoter regions that have binding sites for transcription factors such as AP-1 ,
SP-1 and Egr-1 , which are relevant for TFPI-2 gene expression . As shown in fig .
5, Region I is closer to the transcription start site (TSS) and covers binding sites
for AP-1 , SP-1 and Egr-1. Region II is further away from the TSS and covers an
area with several binding sites for AP-1 .

-c::

LI

~

I

o

CI>

a:

SP-I binding site

~

Egr-l bind ing site

AP -I bin d in g Sit e

Fig.5 Schematic illustration of the TFPI-2 gene and the regions amplified by
the ChIP primers (Regions I and II)

TIS, transcription initiation site; TSS , translation start site ; TSC, translation stop
codon ; TTS, transcription termination site. Modified from Chand HS et al. 15
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In this study, we investigated whether curcumin induces changes in the
histone H3 acetylation at the TFPI-2 promoter, that are relevant for the regulation
of transcription. Specifically, histone H3 acetylation at Iysines 9 and 14 (H3Ac)
was examined. This modification is transcriptionally permissive in the promoter
region and represents 'open chromatin'. Cells were plated and treated with
curcumin as described in earlier experiments. At 24 hours, the cells were fixed
with formaldehyde, enzyme digested, and immunoprecipitated with anti-H3Ac
antibody. DNA obtained after immunoprecipitation was reverse cross-linked and
amplified with the RT-PCR primers mentioned above (methods). TSA, being an
HDAC inhibitor, was used as a control in these experiments.

H3Ac at TFPI-2 Promoter region I
8
7

..... 6

=>
~

5

>
o
32

4
3
2

Q)

~

1

o
UT

Cur 25

TSA

Fig.6 Curcumin increases histone H3 acetylation at the TFPI-2 promoter
(Region I)
Cells were left untreated (UT) or treated with curcumin (25 11M) or TSA (300
ng/ml) for 24 hours. Chromatin was collected and ChiP RT-PCR was performed
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for detection of H3Ac at Region I of the TFPI-2 promoter. The data is a
representation of three independent experiments.
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Fig.7 Curcumin increases histone H3 acetylation at the TFPI-2 promoter
(Region II)

Cells were left untreated (UT) or treated with curcumin (25 11M) or TSA (300
ng/ml) for 24 hours. Chromatin was collected and ChiP RT-PCR was performed
for detection of H3Ac at Region II of the TFPI-2 promoter. The data is a
representation of three independent experiments.
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epG island methylation at nucleotide positions -93 and -32 of the TFPI-2
promoter is unaffected by curcumin

Another epigenetic mechanism that contributes to silencing of genes is
hypermethylation of the cytosines of the CpG sites in gene promoter regions.
TFPI-2 promoter methylation has been detected in 80% of HCC cell lines and
47% of human HCCs in a study by Wong et. a1. 9 . Aberrant promoter methylation
has also been shown to correlate with silencing of TFPI-2 in gastric and
pancreatic tumors. Hence, it is important to examine the effect of curcumin on the
methylation CpG sites in the TFPI-2 promoter.
Bisulfite conversion of DNA and methyl-specific RT -PCR was used to
examine the methylation status of CpG sites at nucleotide positions -93 and -32
of the TFPI-2 promoter, as described earlier in the methods chapter. Completely
methylated human DNA and completely unmethylated human DNA were used as
controls. The TFPI-2 promoter was found to be mostly unmethylated at the sites
investigated by the primer set used as indicated by the faint band of methylated
DNA. Further, there was no observable difference in the faint methylated DNA
band after treatment with (25 11M) curcumin for 24 hours (fig. 8)
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Fig. 8 TFPI-2 is mostly unmethylated at nucleotide positions -93 and -32 in
the promoter region
Cells were left untreated (UT) or treated with curcumin (25 11M) for 24 hours.
DNA was collected , bisulfite converted and amplified by methyl-specific PCR.
Methyl-specific primer sets for a single site in the TFPI-2 promoter were used.
M = Human methylated DNA control , U = Human unmethylated DNA control

24

Curcumin reduces cell invasiveness of HepG2 cells

TFPI-2 is a matrix-associated Kunitz-type serine proteinase inhibitor, and
plays an important role in normal extracellular matrix (ECM) remodeling. The
proteinases inhibited by TFPI-2 in the ECM are not known with certainty.
However, studies have shown that TFPI-2 inhibits plasmin in vitro and most likely
in vivo. Recent reports have also demonstrated that TFPI-2 probably inhibits
matrix metalloproteinases directly in the ECM. Loss of TFPI-2 thus allows for
degradation of the ECM, which is a critical step in the process of tumor invasion
and spread.
In order to study the effect of curcumin on cellular invasiveness in HCC,
we performed a cell invasion assay. HepG2 cells were plated, treated with 15 j.1M
curcumin for 24 hours and allowed to pass through a rehydrated basement
membrane as per manufacturer's protocol (see methods). Curcumin reduced cell
invasion across the membrane, as shown by the stained inserts and by
colorimetric quantification in fig. 9.
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Figs. 9 (a) and (b) Curcumin reduces cell invasiveness in HepG2 cells
Cells were left untreated (UT) or treated with 15 11M curcumin and allowed to
invade a rehydrated basement membrane in the cell invasion assay. Staining of
invasive cells is shown in fig. 9 (a). The invaded cells were then collected, lysed
and a colorimetric quantification was performed, as shown in fig. 9 (b).

26

Curcumin reduces HepG2 cell survival

Restoration

of

TFPI-2

in

tumors

inhibits

cell

proliferation

and

angiogenesis, besides reducing cellular invasiveness 9 . Ectopic overexpression of
TFPI-2 has also been shown to reduce cell growth in HCC cell lines 9 . TFPI-2
triggered apoptosis in a glioblastoma cell line, probably via a caspase-mediated
mechanism 23 •
We examined the effects of curcumin on cell survival in HepG2 cells using
two assays - the MTT assay and the CeliTiter-Glo® Luminescent Cell Viability
assay. The MTT assay measures the activity of enzymes that reduce MTT to
purple formazan, and thus, is a measure of viable and active cells. Compared
with untreated cells, curcumin-treated cells demonstrated reduced cell viability in
the MTT assay at 24 hours (fig. 10). The CeliTiter-Glo® Luminescent Cell
Viability assay is a homogeneous method to determine the number of viable cells
in culture based on quantification of the ATP present, which signals the presence
of metabolically active cells. Curcumin led to a significant reduction in ATP
production between the concentrations of 12.5 and 50 11M. Moreover, a dosedependent decrease in cell viability between the concentration range of 12.5 and
35 11M was observed (fig. 11).
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Fig. 10 Curcumin displays cytotoxicity of HepG2 cells
Cells were left untreated (UT) or treated with curcumin (15 and 25 11M) for 24
hours and the MTT assay was performed. Data is presented as mean ± SO , n=3,
* p<0.05 when compared to UT
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Fig.11 Curcumin reduces cell viability of HepG2 cells
Cells were left untreated (UT) or treated with curcumin (6.25 to 50 11M) for 24
hours and the CeIiTiter-Glo® Luminescent Cell Viability assay was performed .
Data is presented as mean ± SEM , n=2; **p<0.01, *** p<0.0001 when compared
to UT. a, b = p<0.01
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CHAPTER IV
SIGNIFICANCE AND CLINICAL RELEVANCE

All the current therapeutic options for the management of HCC have
proven inadequate and do not offer satisfactory outcomes. There continues to be
an acute need for effective therapies. Moreover, the need is getting increasingly
bigger with the rapidly rising incidence of this highly lethal cancer. Combinatorial
therapy is the cornerstone of most cancer therapy regimens today. Even in the
case of HCC, combination therapy or adjuvant chemotherapy appears to be the
most promising option for effective control. Adjuvant chemotherapy aimed at
epigenetic modulation may afford even more benefit, given that epigenetic
modifications playa role in HCC pathogenesis33 . Curcumin has the potential to
be an effective adjuvant chemotherapeutic agent, and could possibly enhance
results of traditional chemotherapy through its unique mechanism of action.
Along with present chemotherapies that mostly aim at tumor control by inhibition
of DNA synthesis, derepression of critical silenced tumor suppressor genes,
namely TFPI-2, by curcumin may provide more effective inhibition of tumor
progression and metastasis. Adjuvant curcumin therapy will allow for reduction of
dose of the more toxic anti-cancer drugs 33 . Moreover, as it is a natural compound
with no side-effects or toxicity to normal cells, curcumin is not expected to cause
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any toxic side-effects of its own. Several groups are currently working on the
formulation of effective drug delivery systems for the administration of curcumin.
In our future studies, we propose to use liposome encapsulated curcumin in an in

vivo rat HCC model to improve the bioavailability of curcumin. With a wellelucidated mechanism of action in relation to TFPI-2 and an improved delivery
system, curcumin could offer tremendous benefit to HCC patients as well as
persons at risk for HCC development. The low cost and non-existent side-effect
profile of curcumin only make it more promising as an ideal adjuvant
chemotherapeutic drug.
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CHAPTER V
FUTURE STUDIES

In further studies with curcumin and TFPI-2, we will investigate other
epigenetic modifications that may be involved in curcumin-induced TFPI-2
reactivation. To this end, we will study histone H3 tri-methylation at lysine 4
(H3K4Me3), which denotes transcriptionally permissive chromatin. Histone 3
methylation at Kg and tri-methylation at K27, both of which represent
transcriptionally repressive states, will also be examined. Also, DNA methylation
at other sites in the TFPI-2 promoter will be examined using different primer sets.
Binding of transcription factors and RNA polymerase II will also be studied. To
assess the contribution of the reactivation of TFPI-2 to the anti-HCC effects of
curcumin, HepG2 cells will be transfected with siRNA for TFPI-2 and cell survival
and cell invasion assays will be performed.
The effects of curcumin on other tumor suppressor genes will also be
examined in the future. The combinatorial effects of curcumin with current
chemotherapeutic

agents

will

be

assessed,

to

study

a

potential

adjuvant/combinatorial chemotherapeutic role for curcumin.
Finally, we propose to characterize the in vivo effects of curcumin using
liposome-encapsulated curcumin in our rat xenograft model of HCC.
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CHAPTER VI
SUMMARY

The goal of our study was to examine the anti-HCC effect of curcumin with
respect to the derepression of the critical tumor suppressor gene, TFPI-2.
Curcumin was observed to robustly reactivate TFPI-2 in HepG2 cells. TFPI-2 is
epigenetically regulated in HCC cells. We therefore examined the epigenetic
modifications at the TFPI-2 promoter region, specifically histone acetylation and
DNA methylation as influenced by curcumin. Histone H3 acetylation at the
transcription factor binding sites of the TFPI-2 promoter region was increased by
curcumin and correlated with the induction of gene expression. This is the likely
mechanism by which curcumin reactivates TFPI-2. The TFPI-2 promoter was
found to be only slightly methylated at the single site investigated in this work and
was not influenced by curcumin. However, other sites in the TFPI-2 promoter
region need to be examined to fully characterize the effect of curcumin on CpG
island methylation. Corresponding to the reactivation of TFPI-2, curcumin also
induced cell death and reduced cell invasiveness in HepG2 cells. Further studies
will examine the contribution of the epigenetic reactivation of TFPI-2 towards
these anti-HCC effects.
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Given the acute need for novel therapeutic options in the management of
HCC, these studies have the potential to provide a basis for the development and
use of curcumin in the clinical setting.
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